Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Sodium channel protein type 5 subunit alpha

2

Sodium channel protein type 9 subunit alpha

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1985

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Chronic pain from amputation

2

Life-threatening arrhythmias

2

Muscle cramps in amyotrophic lateral sclerosis

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Boehringer Ingelheim

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

CHEBI

2

ChEMBL

2

DAILYMED

2

DRUG BANK

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

CARDIAC THERAPY

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIARRHYTHMICS, CLASS I AND III

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antiarrhythmics, class Ib

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

MEXILETINE

1U511HHV4Z

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1985

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Sodium channel protein type 5 subunit alpha

Sodium channel protein type 9 subunit alpha

Conditions:

Muscle cramps in amyotrophic lateral sclerosis

Life-threatening arrhythmias

Chronic pain from amputation

Mexiletine is a non-selective voltage-gated sodium channel blocker which belongs to the Class IB anti-arrhythmic group of medicines. It is used to treat heart arrhythmias. Mexiletine is also used to treat refractory pain and muscle stiffness resultin...

g in myotonic dystrophy or myotonia congenita. Mexiletine was approved for commercial use in 1985 under the brand name Mexitil, but most marketing efforts have since been discontinued. There has been a continued effort to identify other therapeutic use cases and a number of clinical trials have been conducted including ALS and chronic pain from amputation.

MEXILETINE HYDROCHLORIDE

606D60IS38

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1985

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Sodium channel protein type 5 subunit alpha

Sodium channel protein type 9 subunit alpha

Conditions:

Muscle cramps in amyotrophic lateral sclerosis

Life-threatening arrhythmias

Chronic pain from amputation

Mexiletine is a non-selective voltage-gated sodium channel blocker which belongs to the Class IB anti-arrhythmic group of medicines. It is used to treat heart arrhythmias. Mexiletine is also used to treat refractory pain and muscle stiffness resultin...

g in myotonic dystrophy or myotonia congenita. Mexiletine was approved for commercial use in 1985 under the brand name Mexitil, but most marketing efforts have since been discontinued. There has been a continued effort to identify other therapeutic use cases and a number of clinical trials have been conducted including ALS and chronic pain from amputation.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1